Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 Sep 20, 2022
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis Sep 19, 2022
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 Jul 25, 2022
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe Jul 22, 2022
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance Jul 14, 2022
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Jun 3, 2022
